November 2024 Content Release Copied

11/21/20242024 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

Additions

The following Curbside Connect scheduling options have been added for the following diagnoses:

  • Curbside Connect with Douglas Reznick is now available for scheduling in Lung Cancer, Non-small Cell (NSCLC).
  • Curbside Connect with Tobenna Nwizu is now available for scheduling in Colon Cancer and Rectal Cancer.
  • HER2-Low Curbside Connect with Nina Balanchivadze is now available for scheduling in Breast Cancer.

Problem Groups

Additions

The Problems > Add Details area now includes applicable documentation points for the following diagnoses.

EGFR status is now updated for Lung Cancer, Non-small Cell (NSCLC) with the following documentation points:

  • Exon 19 deletion or Exon 21 L858R
  • S768I, L861Q, and/or G719X
  • T790M mutation
  • Exon 20 insertion mutation
  • Negative
  • Other non-actionable finding
  • Unknown

Problems

Additions

New items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes may be displayed to present the surrounding nodes.

  • Bone marrow Metastasis

Lab Analytes & Panels

Additions

Analytes

  • Anaerobe gram stain
  • Atypical ANCA
  • Myeloma, FISH tissue ID
  • Myeloma, FISH, tissue disclaimer
  • Myeloma, FISH, tissue interpretation
  • Myeloma, FISH, tissue method
  • Myeloma, FISH, tissue reason for referral
  • Myeloma, FISH, tissue released by
  • Myeloma, FISH, tissue result
  • Myeloma, FISH, tissue result summary
  • Myeloma, FISH, tissue result table
  • Myeloma, FISH, tissue source
  • Myeloma, FISH, tissue specimen
  • OnkoSight advanced NGS comprehensive myeloid panel result
  • OnkoSight advanced NGS detailed genetic interpretation 1
  • OnkoSight advanced NGS interpretation summary
  • OnkoSight advanced NGS methods
  • OnkoSight advanced NGS references 1
  • OnkoSight advanced NGS report footer
  • OnkoSight advanced NGS technical summary
  • OnkoSight NGS JAK2 Exon12 sequencing interpretation summary
  • OnkoSight NGS JAK2 Exon12 sequencing methods
  • OnkoSight NGS JAK2 Exon12 sequencing panel
  • OnkoSight NGS JAK2 Exon12 sequencing references 1
  • OnkoSight NGS JAK2 Exon12 sequencing report footer
  • PTT-LA screen (PTT-D)

Panels

  • BRACAnalysis and MyRisk panel
  • BRACAnalysis CDx and MyRisk panel
  • BRACAnalysis CDx panel
  • Colaris and MyRisk panel
  • Colaris AP and MyRisk panel
  • Colaris AP plus panel
  • Colaris plus panel
  • FoundationOne Dako PD-L1 IHC 28-8 panel
  • FoundationOne FoundationOneCDx and FoundationOneRNA panel
  • FoundationOne FoundationOneHeme panel
  • FoundationOne PD-L1 IHC (Dako 22C3 pharmDx)
  • FoundationOne tracker panel
  • FoundationOne Ventana PD-L1 (SP142) panel
  • FoundationOne Ventana PD-L1 (SP263) panel
  • Integrated BRACAnalysis (BRCA1 BRCA2 only) panel
  • Myriad MyRisk update test panel
  • Osteocalcin panel, serum
  • Osteocalcin, serum, ng/mL
  • Single-site include gene and mutation name panel
  • Tempus xT (v2) original panel

Medications

Additions

  • AB680 invest IV
  • APG-2575 invest Oral
  • AVZO-021 (ARTS-021) invest Oral
  • BGB-16673 invest Oral
  • BMS-986369/CC-99282 invest Oral
  • BNT317 invest IV
  • CC-220 invest Oral
  • CC-92480 invest Oral
  • CD19 t-haNK invest IV
  • Divarasib invest (RO7435846 invest Oral)
  • FMC-376 invest Oral
  • FX-909 invest Oral
  • Golcadomide invest (BMS-986369/CC-99282 invest Oral)
  • HM16390 invest Subcutaneous
  • IBI363 invest IV
  • INKmune invest IV
  • Lisaftoclax invest (APG-2575 invest Oral)
  • Mezigdomide invest (CC-92480 invest Oral)
  • NMS-03597812 invest Oral
  • Quemliclustat invest (AB680 invest IV)
  • RO7435846 invest Oral
  • SGN-B7H4V invest IV
  • VNX-101 (AAVrh.74hCD19/CD3-scFv) invest IV

Updates

Medication Update
ALT2618 invest Oral Updated Drug Name: ALTA2618 invest Oral
DS-6000a invest IV New Alias available:

  • Raludotatug Deruxtecan (R-DXd) invest

New Quick Sig Pick available:

  • 4.8 mg/kg intravenously once
  • 5.6 mg/kg intravenously once
  • 6.4 mg/kg intravenously once
Iberdomide invest Oral Updated Drug Name: CC-220 invest Oral
KB-GDT-01 invest IV Updated Drug Form to: 2x10e7 viable cells/mL in 10 mL CryoStor/50mL cryobag
Testosterone Sublingual New Name available: Compounded Testosterone

Regimen Library

Additions

Regimen Name Diagnosis
Abiraterone + Prednisone + Relugolix Q28D Prostate Cancer
Apalutamide + Relugolix Q30D Prostate Cancer
Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Zolbetuximab-clzb Q21D Esophageal Cancer (Parent); Gastric Cancer
Darolutamide + Relugolix Q30D Prostate Cancer
Docetaxel + Abiraterone + Prednisone + ADT Q30D (Abiraterone + Prednisone + Relugolix only) Prostate Cancer
Docetaxel + Darolutamide + ADT Q28D (Darolutamide + Relugolix only) Prostate Cancer
Enzalutamide + Relugolix Q28D Prostate Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) D1,15,29 + Zolbetuximab-clzb D1,22 Q42D Esophageal Cancer (Parent); Gastric Cancer
Venetoclax D1-14 + Decitabine and Cedazuridine (Inqovi) D1-5 Q28D Myelodysplastic Syndrome (MDS)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • All Problems
  • Bladder Cancer
  • Breast Cancer
  • Esophageal Cancer (Parent)
  • Head and Neck Cancer (Parent)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Melanoma, Skin
  • Myelodysplastic Syndrome (MDS)
  • Myelofibrosis
  • Prostate Cancer
  • Renal Pelvis and Ureter Cancer
  • Sarcoma, Soft Tissue (Parent)
  • Urethral Cancer

Renames

Previous Name New Name
Atezolizumab Q21D (Adjuvant NSCLC) Atezolizumab IV Q21D (Adjuvant NSCLC)
Atezolizumab Q14D Atezolizumab IV Q14D
Atezolizumab Q21D Atezolizumab IV Q21D
Atezolizumab Q28D Atezolizumab IV Q28D
Atezolizumab Q21D (Adjuvant NSCLC) Atezolizumab IV Q21D (Adjuvant NSCLC)
Docetaxel + Carboplatin Q21D (Breast) Docetaxel + Carboplatin Q21D (Triple Negative Breast)
Nivolumab Q28D (Flat Dose) (Adjuvant Melanoma, Esophageal, Bladder) Nivolumab Q28D (Flat Dose) (Adjuvant Melanoma, Esophageal, Bladder, NSCLC)
Vemurafenib + Cobimetinib D1-21 Q28D fb Vemurafenib + Cobimetinib D1-21 + Atezolizumab D1,15 Q28D Vemurafenib + Cobimetinib D1-21 Q28D fb Vemurafenib + Cobimetinib D1-21 + Atezolizumab IV D1,15 Q28D
Venetoclax + Decitabine D1-5 Q28D (MDS, Myelofibrosis) Venetoclax D1-14 + Decitabine D1-5 Q28D (MDS, Myelofibrosis)

Removals

Regimen Name Diagnosis
Aducanumab-avwa Q28D Alzheimer’s disease

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
Aflibercept-ayyh Intravitreal J3590 per 2mg
Atezolizumab-Hyaluronidase-tqjs Subcutaneous J9999 per 15mL
Bendamustine IV J9036 per 1mg
Iloprost IV J1749 per 0.1mcg
Lacosamide IV J3490 per 200mg
Zolbetuximab-clzb IV J9999 per 100mg